Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 12, 2017

Takeda reports positive Phase lll data of adcetris combination

Takeda Pharmaceutical Company and Seattle Genetics have reported positive results in a Phase lll clinical trial assessing adcetris (brentuximabvedotin) under a frontline combination chemotherapy regimen for untreated advanced classical Hodgkin's lymphoma.

Takeda Pharmaceutical Company and Seattle Genetics have reported positive results in a Phase lll clinical trial assessing adcetris (brentuximabvedotin) under a frontline combination chemotherapy regimen for untreated advanced classical Hodgkin’s lymphoma.

The study is a part of the randomised, open-label, two-arm, multi-centre Phase lll ECHELON-1 trial.

ECHELON-1 study met its primary endpoint with the combination of ADCETRIS+AVD, resulting in a statistically significant improvement in modified progression-free survival (PFS) versus the control arm of Adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) as evaluated by an independent review facility (IRF).

The achievement represents a 23% reduction in the risk of progression, death or need for additional anticancer therapy.

Each IRF assessment showed that the two-year modified PFS rate for patients in the ADCETRIS+AVD arm stood at 82.1% compared with 77.2% in the control arm.

“Takeda and Seattle Genetics aim to provide the adcetris-containing regimen to patients with advanced Hodgkin’s lymphoma in the US by the first half of next year.”

In every investigator assessment, the two-year modified PFS rate for patients in the ADCETRIS+AVD arm was 81% compared with 74.4% in the control arm, marking a 27% reduction in the risk of progression, death or need for additional anticancer therapy.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

All the secondary endpoints of the Phase lll ECHELON-1 trial also favoured the ADCETRIS+AVD arm, including an interim analysis of overall survival and others.

Takeda vice-president and Oncology Clinical Research and Development head Jesús Gomez Navarro said: “For patients with advanced-stage Hodgkin’s lymphoma, approximately one in three do not achieve long-term remission after standard frontline therapy, which is why the results of ECHELON-1 could be important to this group of patients.”

Takeda and Seattle Genetics aim to provide the adcetris-containing regimen to patients with advanced Hodgkin’s lymphoma in the US by the first half of next year.

Adcetris is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical Hodgkin’s lymphoma and is currently not approved as a frontline therapy for the disease.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU